IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4058
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$543M
Brian M. Stuglik
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Headcount
50
HQ Base
NEEDHAM, Massachusetts
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$VSTM Verastem, Inc. | 36 | 38 | 33 | 33 | - | - | -2888.7% | -113.4% | 85.0% | -1205.0% | -1045.0% | 12.4% | 0.0% | - | $543M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Verastem, Inc. (VSTM) receives a "Avoid" rating with a composite score of 35.5/100. It ranks #4058 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for VSTM.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 38 | 26 | +12ALPHA |
| MOMENTUM | 33 | 20 | +13ALPHA |
| VALUATION | 33 | 22 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 42 | 33 | +9ALPHA |
| SHORT INT | 32 | 22 | +10ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -2888.7% (sector -1.9%)
GM 85% vs sector 44%, OM -1205% vs sector 3%
Capital turnover N/A, R&D intensity 619.8%
Rev growth 12%, 10yr history
Interest coverage -127.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Verastem, Inc. (VSTM) as Avoid with a composite score of 35.5/100 at a current price of $5.89. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Verastem, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.5/100 places it at rank #4058 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 85% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Verastem, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Verastem, Inc. with an Avoid rating, assigning a composite score of 35.5/100 and 1 out of 5 stars. Ranked #4058 of 7,333 stocks, VSTM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
VSTM's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -2888.7% (sector avg: -1.9%), gross margins of 85.0% (sector avg: 44.1%), net margins of -1045.0% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 33/100, VSTM appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Verastem, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 12.4% vs. a sector average of 6.7% and a return on assets of -113.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
VSTM is currently showing below-average momentum at 33/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 12.4% year-over-year, while a beta of 1.27 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
VSTM's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.27. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Verastem, Inc.'s short interest score of 32/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.27), small-cap liquidity risk. At $543M (small-cap), VSTM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Verastem, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4058 of 7,333 overall (45th percentile). Key comparisons include ROE of -2888.7% trailing the -1.9% sector median and operating margins of -1205.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While VSTM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 151937% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 93% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 48110% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
BOSTON, February 18, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ: MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated video modernization with NVIDIA at the ACM Mile-High-Video 2024 conference. DIH Holdings US, Inc. (NASDAQ: DHAI) shares climbed 65.2% to $2.1306. DIH Holding US secured $1.5 million in private placement financing from OrbiMed. ContextLogic Inc. (NASDAQ: WISH) gained 40.2% to $6.31 after the company announced an agreement to sell substantially all of its operating assets and liabilities to Qoo10 for approximately $173 million in cash. SuperCom Ltd. (NASDAQ: SPCB) shares jumped 40% to $0.2570. SuperCom recently disclosed that it has secured a new contract with an established California services provider in the judicial sector. Intuitive Machines, Inc. (NASDAQ: LUNR) shares gained 33.3% to $6.65 after jumping around 32% on Friday. D-Wave Quantum Inc. (NYSE: QBTS) gained 31% to $1.4295. Renalytix Plc (NASDAQ: RNLX) surged 27% to $0.4842. Genasys Inc. (NASDAQ: GNSS) gained 27% to $1.98. Genasys bagged critical infrastructure project to engineer, procure and build emergency warning system for 37 dams across the island of Puerto Rico. Root, Inc. (NASDAQ: ROOT) rose 22.6% to $9.30. Syra Health Corp. (NASDAQ: SYRA) ...
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.